Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal microbiota transplantation as maintenance after anti-TNF withdrawal in Crohn's disease
2019-003816-29Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2019
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fecal microbiome transplant in Crohn's disease (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Clinical remission at week 52 without flare. Started Oct 2019; status: active.
02
Drugs
fecal microbiome transplant
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2019-003816-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003816-29.